Enzyme Therapeutics and Replacement

Enzyme therapeutics and replacement comprises the strategies that address enzyme-deficiency disorders by restoring or compensating for missing catalytic activity. The best-established is enzyme replacement therapy, in which a recombinant form of the deficient enzyme is administered to take over its biochemical role, first achieved for Gaucher disease.

Definition

Enzyme replacement therapy is the administration of an exogenous, usually recombinant, enzyme to supply catalytic activity that is deficient because of an inherited enzyme defect; the broader topic of enzyme therapeutics also includes strategies that enhance residual activity or reduce the substrate that the enzyme would normally process.

Scope

This topic covers the rationale and main approaches of enzyme-directed therapy for inborn enzyme deficiencies: enzyme replacement therapy, enzyme-enhancement and substrate-reduction strategies, and their known limitations such as delivery to the central nervous system. It is framed as a biochemical and translational overview and contains no dosing or individualised treatment guidance.

Core questions

• How can an administered enzyme be delivered to the cells and compartments where it is needed?
• Why has enzyme replacement been most successful for lysosomal storage diseases?
• What limits the approach, particularly for disease affecting the central nervous system?
• How do enzyme replacement, enzyme enhancement, and substrate reduction differ in mechanism?

Key concepts

• Enzyme replacement therapy
• Recombinant enzyme
• Cell-surface receptor targeting
• Mannose and mannose-6-phosphate uptake
• Substrate reduction therapy
• Pharmacological chaperones (enzyme enhancement)
• Blood-brain barrier as a delivery barrier

Mechanisms

In enzyme replacement therapy, a recombinant enzyme is infused and taken up by cells through surface receptors, often carbohydrate-recognition receptors that route the enzyme to the lysosome where the deficient activity is needed; the macrophage-targeted glucocerebrosidase used in Gaucher disease is the archetypal example. Complementary strategies act differently: substrate-reduction therapy lowers production of the substrate so that residual enzyme can cope, and enzyme-enhancement (chaperone) approaches stabilise a misfolded but partly functional enzyme to raise its activity. A central limitation is delivery, especially across the blood-brain barrier, which restricts efficacy in disorders with prominent central nervous system involvement.

Clinical relevance

These approaches transformed the prospects of several previously untreatable enzyme-deficiency disorders and illustrate how understanding an enzyme defect leads to rational therapy. This entry describes the principles and history of enzyme-directed therapy for reference and education; it does not provide dosing, eligibility, or individualised treatment advice.

History

The field was opened by the demonstration that infused, macrophage-targeted glucocerebrosidase could treat Gaucher disease, reported in 1991 after years of work on enzyme targeting. Reviews then synthesised the lessons from lysosomal disorders, including the importance of receptor-mediated uptake and the persistent difficulty of treating central nervous system disease, and the approach expanded to additional enzyme-deficiency conditions.

Debates

How can enzyme therapy reach the central nervous system?

Infused enzymes are largely excluded from the brain by the blood-brain barrier, so disorders with prominent neurological involvement respond poorly to conventional enzyme replacement; approaches to overcome this remain an active area of investigation.

Key figures

• Roscoe Brady
• Norman Barton
• Robert Desnick
• Elizabeth Neufeld

Seminal works

• barton-1991
• desnick-2002
• brady-2006

Frequently asked questions

What was the first disease treated by enzyme replacement therapy?

Gaucher disease; the 1991 demonstration that macrophage-targeted glucocerebrosidase could replace the missing enzyme established the approach.

Why is enzyme replacement less effective for brain involvement?

Infused enzymes are largely kept out of the central nervous system by the blood-brain barrier, so disorders with major neurological features respond poorly to standard intravenous enzyme replacement.